Sosei Group Corporation announced at its board of directors meeting held on May 15, 2018 appointment of Dr. Michael Hayden, Mr. Kuniaki Kaga and Dr. David Roblin as an external directors. The purpose of this appointments is to enhance the supervisory function of the Board of Directors, provide experienced oversight of research and development pipeline, and improve management transparency, with the aim of enhancing overall corporate governance system. Dr. Michael Hayden was former Global R&D President and Chief Scientific Officer at Teva Pharmaceuticals. Mr. Kuniaki Kaga was former Board Director, Representative Director and Senior Managing Executive Officer at Mitsubishi Tanabe Pharma Corporation and Dr. David Roblin was former Senior Vice President, Head of Research, and Chief Medical Officer Europe R&D at Pfizer Inc.